Immunomodulatory and Antimicrobial Efficacy of Intravenous Immunoglobulin in Bone Marrow Transplantation
- 13 September 1990
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (11), 705-712
- https://doi.org/10.1056/nejm199009133231103
Abstract
Graft-versus-host disease (GVHD) and infection are major complications of allogeneic bone marrow transplantation. Since intravenous immunoglobulin has shown benefit in several immunodeficiency and autoimmune disorders, we studied its antimicrobial and immunomodulatory role after marrow transplantation. In a randomized trial of 382 patients, transplant recipients given immunoglobulin (500 mg per kilogram of body weight weekly to day 90, then monthly to day 360 after transplantation) were compared with controls not given immunoglobulin. By chance, the immunoglobulin group included more patients with advanced-stage neoplasms; otherwise, the study groups were balanced for prognostic factors. Control patients seronegative for cytomegalovirus who received seronegative blood products remained seronegative, but seronegative patients who received immunoglobulin and screened blood had a passive transfer of cytomegalovirus antibody (median titer, 1:64). Among the 61 seronegative patients who could be evaluated, none contracted interstitial pneumonia; among the 308 seropositive patients evaluated, 22 percent of control patients and 13 percent of immunoglobulin recipients had this complication (P = 0.021). Control patients had an increased risk of gram-negative septicemia (relative risk = 2.65, P = 0.0039) and local infection (relative risk = 1.36, P = 0.029) and received 51 more units of platelets than did imunoglobulin recipients. Neither survival nor the risk of relapse was altered by immunoglobulin. However, among patients ≥20 years old, there was a reduction in the incidence of acute GVHD (51 percent in controls vs. 34 percent in immunoglobulin recipients; P = 0.0051) and a decrease in deaths due to transplant-related causes after transplantation of HLA-identical marrow (46 percent vs. 30 percent; P = 0.023). Passive immunotherapy with intravenous immunoglobulin decreases the risk of acute GVHD, associated interstitial pneumonia, and infections after bone marrow transplantation. (N Engl J Med 1990; 323: 705–12.)Keywords
This publication has 54 references indexed in Scilit:
- Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1989
- Graft-versus-Host Disease as Adoptive Immunotherapy in Patients with Advanced Hematologic NeoplasmsNew England Journal of Medicine, 1989
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987
- Prevention ofHaemophilus influenzaeType b Infections in High-Risk Infants Treated with Bacterial Polysaccharide Immune GlobulinNew England Journal of Medicine, 1987
- The Treatment of Kawasaki Syndrome with Intravenous Gamma GlobulinNew England Journal of Medicine, 1986
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationNew England Journal of Medicine, 1986
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- Graft-versus-Host Disease and Survival in Patients with Aplastic Anemia Treated by Marrow Grafts from HLA-Identical SiblingsNew England Journal of Medicine, 1983